Researchers from the University of Washington School of Medicine in Seattle have identified the 6-4 photoproducts (6-4PPs) as the lesion responsible for DNA damage related to ultraviolet (UV) light exposure, as well as another lesion, cyclobutene pyrimidine dimers (CPDs), which can be attributed to affecting a cell’s reaction to UV.

Demonstrated within an analysis completed on the COMBI-AD trial, adjuvant dabrafenib and trametinib provided long-term benefit for patients with resected stage III BRAF V600-mutant melanoma. In a statement to Healio, Axel Hauschild, MD, PhD, professor of dermatology at University Hospital Schleswig-Holstein Campus Kiel in Germany stated: "Even though it met my expectation, to have 50% of patients with high-risk melanoma still without relapse at 5 years is a very good result.”